Resources

Terms of reference for the Medical Devices and Human Tissue Advisory Committee.

This report provides an assessment of the clinical needs and impacts of technical services in association with CIEDs.

This document contains a breakdown of each General Use Item Bundle. They are shown by Product Branch Code, Product Branch Descriptor, Product Class Code, Product Class Description, Variant Branch Code, Variant Branch Description, Bundle Variant Code, Bundle Variant Description and Bundle Benefit.

This agreement with the Medical Technology Association of Australia (MTAA) supports sponsors and suppliers of medical devices. It runs from 15 October 2017 to 31 January 2022.

This report provides an analysis of stakeholder feedback received in response to the Prostheses List Reform Consultation Paper 6a – Listing Criteria.

This report provides an analysis of stakeholder feedback received in response to the Prostheses List Reform Consultation Paper 6a - Listing Criteria.

Find out about the hibernation of all Prostheses List reform work covered under the Agreement with the MTAA. The work will pause for up to 12 months.

This guideline lists the 13 parameters you must address when applying to add a Trans-Aortic Valve Implantation (TAVI) device to the Prostheses List.

A Budget 2021–22 fact sheet.

This report describes the proceedings of the Revised Benefit Setting and Review Framework Industry Working Group (BSRIWG) over 8 meetings held between April 2018 and February 2020.

These attachments to PHI circular 62/23 are the 2024 private health insurance premium application form and templates.

These guidelines set out how PLAC will operate to deliver on its Terms of Reference.

This document sets out the purpose, roles, function and composition of PLAC.

This Memorandum of Understanding (MoU) between the Minister for Health and Aged care and the Medical Technology Association of Australia.

The executive summary shows the stakeholder views to improvements to the Protheses List (PL) as announced in the 2021–22 Federal Budget.

The purpose of this paper is to clarify details of the government’s decision to better define the PL purpose, definitions, and scope and explore how this might be implemented in delegated legislation and the guidance.

The below data documents detail cardiac implantable electronic devices (CIEDs) that will have their Prostheses List (PL) benefits reduced by 40% of the gap on 1 July 2023.

This report provides an analysis of stakeholder feedback received in response to the Prostheses List Reform Consultation Paper 6b Cost Recovery Arrangements.

The Australian Government is investing $22 million over 4 years to modernise and improve the Prostheses List (PL). This includes addressing issues raised by recent reviews of the scope and operation of PL.

This report provides an analysis of stakeholder feedback requested through webinars and written responses to the Prostheses List reforms consultation paper 4 (a) and 4 (b).